BioNTech Takes Its Oncology Ambitions to ASCO Backed by €19.6B and a Potential First Approval
26.05.2026 - 09:43:34 | boerse-global.de
When BioNTech executives step onto the floor of the ASCO annual meeting in Chicago on May 29, they will do so with a war chest of nearly €20 billion and a pipeline that has never been under closer scrutiny. The German biotech, which rode the Covid-19 vaccine wave to global fame, is now trying to convince investors that it can reinvent itself as a diversified oncology powerhouse. The next week will be critical: new clinical data, a possible path to the company’s first U.S. cancer drug approval, and a stock that has lost a tenth of its value in the past month are all converging.
The financial pressure is real. In its most recent quarter, BioNTech’s revenue slumped to €138 million as Covid vaccine sales continued their structural decline. The net loss widened to €622 million, while research and development spending climbed to roughly €652 million, driven by investments in the core oncology pipeline. For the full year 2026, BioNTech has held its revenue forecast steady at €2.3 billion to €2.6 billion. The cash pile stood at €19.6 billion at the end of March, a cushion that funds not only the R&D push but also a share buyback programme of up to €1 billion over twelve months.
The stock closed at €79.80 on Monday, up 5.4% over the past week but still 10% lower on a 30-day view. It trades about 22% below its 52-week high from last June, and remains 7.6% below its 200-day moving average. The relative strength index sits at 61.6, hinting at a technical rebound, but the market is waiting for substance — and ASCO is where that substance must arrive.
The ADC Arsenal Takes Center Stage
BioNTech will showcase three antibody-drug conjugate programmes at the conference, and the most advanced among them could mark a historic milestone. Trastuzumab Pamirtecan, an ADC targeting HER2-expressing endometrial cancer, delivered a confirmed objective response rate of 47.9% in a phase 2 cohort. Median progression-free survival reached 8.1 months, and importantly, the drug showed efficacy in patients with lower HER2 expression levels (IHC 1+ and 2+) — a population that currently has no approved HER2-directed therapy. The leading competitor, Enhertu, received FDA approval in April 2024 but only for patients with IHC 3+ status. BioNTech and its partner DualityBio plan to submit a Biologics License Application to the FDA later this year. The drug already holds both Fast Track and Breakthrough Therapy designations from 2023. If successful, it would be BioNTech’s first oncology approval in the United States.
Should investors sell immediately? Or is it worth buying BioNTech?
Also under the ASCO spotlight will be BNT326/YL202, an ADC targeting HER3, and BNT324/DB-1311, which targets B7H3 in metastatic castration-resistant prostate cancer. Both are part of the company’s broader push into antibody-drug conjugates, a class of therapies that deliver a cytotoxic payload directly to tumour cells. Four poster presentations related to ongoing studies will flank the main data readouts.
Beyond ADCs: Pumitamig and Gotistobart
BioNTech is not relying solely on ADCs. Pumitamig, a bispecific immunomodulator that combines PD-L1 inhibition with VEGF-A neutralisation, is being developed alongside Bristol Myers Squibb. New phase 2 data from the ROSETTA-Lung-02 study showed encouraging anti-tumour activity in non-small cell lung cancer across all PD-L1 expression levels — the third global dataset to signal consistent efficacy. A phase 3 trial now directly compares Pumitamig with pembrolizumab plus chemotherapy.
Gotistobart, meanwhile, is being tested in heavily pre-treated patients with platinum-resistant ovarian cancer. Phase 2 data from the PRESERVE-004 study demonstrated durable tumour shrinkage and clinically relevant overall survival when combined with pembrolizumab, all without chemotherapy.
A Pipeline Broadening at Speed
BioNTech now has more than 25 clinical trials in advanced stages of development, including 13 ongoing registrational studies. The company expects to launch six additional registrational trials this year, which would bring the total number of planned phase 3 programmes to 15, with seven late-stage data readouts scheduled. Earlier this year, five new registrational studies for Pumitamig began in breast, colorectal, gastric, and two lung cancer settings, with interim results due later in 2026.
BioNTech at a turning point? This analysis reveals what investors need to know now.
To oversee this expansion, BioNTech has strengthened its supervisory board. Shareholders approved an increase from six to eight members, electing Prof. Iris Löw-Friedrich and Susanne Schaffert, both seasoned in oncology development and commercialisation. The appointments underscore the company’s ambition to become a multi-product oncology firm by the end of the decade — not just a pipeline story.
For now, the market’s verdict hinges on data. ASCO will provide concrete points for the thesis that BioNTech can pivot from vaccine champion to broad cancer platform. Strong ADC updates could reinforce that narrative; weak or ambiguous results would raise questions about the pace and credibility of the late-stage programme. With €19.6 billion in the bank and a share buyback signalling capital discipline, BioNTech has the resources to chase its vision. What it lacks is a product on the market — and the next few weeks may determine whether that gap begins to close.
Ad
BioNTech Stock: New Analysis - 26 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
